In relation to branded medicines, there are built in limits to spending increases as a result of the Voluntary Pricing and Access Scheme (VPAS) which it was noted provides a degree of predictability of spending. We were toldiiiHealth and Sport Committee, Official Report, 21 January 2020, Col 9 the UK compares favourably to other countries when it comes to prices paid for generic medicinesiiiHealth and Sport Committee, Official Report, 21 January 2020, Col 10.